-
公开(公告)号:US20130053311A1
公开(公告)日:2013-02-28
申请号:US13516312
申请日:2010-12-16
申请人: Christoph Kalthoff , Jesper Lau , Jane Spetzler , Patrick William Garibay , Jacob Kofoed , Lars Linderoth
发明人: Christoph Kalthoff , Jesper Lau , Jane Spetzler , Patrick William Garibay , Jacob Kofoed , Lars Linderoth
IPC分类号: A61K38/26 , A61P3/10 , C07K14/605
CPC分类号: C07K14/65 , A61K38/00 , A61K47/542 , A61K47/60 , C07K14/605 , G01N2333/605
摘要: The invention relates to a GLP-1 analogue which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1 (7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H31, and the Q residue is designated Q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogues and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.
摘要翻译: 本发明涉及GLP-1类似物,其包含在对应于GLP-1(7-37)(SEQ ID NO:1)的第31位的位置处的组氨酸(H)残基,位置上的谷氨酰胺(Q)残基 对应于GLP-1(7-37)(SEQ ID NO:1)的位置34,与GLP-1(7-37)(SEQ ID NO:1)相比最多为10个氨基酸修饰。 其中H残基指定为H31,Q残基指定为Q34; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其衍生物,以及这些类似物和衍生物的药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病。 本发明还涉及相应的新型侧链中间体。 该衍生物适用于口服给药。
-
公开(公告)号:US08815802B2
公开(公告)日:2014-08-26
申请号:US13516312
申请日:2010-12-16
申请人: Christoph Kalthoff , Jesper Lau , Jane Spetzler , Patrick William Garibay , Jacob Kofoed , Lars Linderoth
发明人: Christoph Kalthoff , Jesper Lau , Jane Spetzler , Patrick William Garibay , Jacob Kofoed , Lars Linderoth
IPC分类号: A61K38/26 , A61P3/10 , C07K14/605 , A61K38/00 , C07K14/65
CPC分类号: C07K14/65 , A61K38/00 , A61K47/542 , A61K47/60 , C07K14/605 , G01N2333/605
摘要: The invention relates to a GLP-1 analog which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1(7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H31, and the Q residue is designated Q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogs and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.
摘要翻译: 本发明涉及GLP-1类似物,其在对应于GLP-1(7-37)(SEQ ID NO:1)的位置31的位置处的组氨酸(H)残基,位置上的谷氨酰胺(Q)残基 对应于GLP-1(7-37)(SEQ ID NO:1)的位置34,与GLP-1(7-37)(SEQ ID NO:1)相比最多为10个氨基酸修饰。 其中H残基指定为H31,Q残基指定为Q34; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其衍生物,以及这些类似物和衍生物的药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病。 本发明还涉及相应的新型侧链中间体。 该衍生物适用于口服给药。
-
公开(公告)号:US09708383B2
公开(公告)日:2017-07-18
申请号:US13882947
申请日:2011-11-09
申请人: Alice Ravn Madsen , Birgit Wieczorek , Jacob Kofoed , Jesper Lau , Jane Spetzler , Janos Tibor Kodra , Lars Linderoth , Patrick William Garibay , Per Sauerberg , Thomas Kruse
发明人: Alice Ravn Madsen , Birgit Wieczorek , Jacob Kofoed , Jesper Lau , Jane Spetzler , Janos Tibor Kodra , Lars Linderoth , Patrick William Garibay , Per Sauerberg , Thomas Kruse
IPC分类号: A61K38/00 , C07K14/605 , A61K47/48
CPC分类号: C07K14/605 , A61K47/542
摘要: The invention relates to a derivative of a GLP-1 analog, which analog comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: HOOC—(CH2)x—CO—* Chem. 1: HOOC—C6H4—O—(CH2)y—CO—* Chem. 2: R2—C6H4—(CH2)z—CO—*, Chem. 3: in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises *—NH—(CH2)2—(O—(CH2)2)k—O—(CH2)n—CO—*. Chem. 4: wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
-
公开(公告)号:US20130288960A1
公开(公告)日:2013-10-31
申请号:US13882947
申请日:2011-11-09
申请人: Alice Ravn Madsen , Birgit Wieczorek , Jacob Kofoed , Jesper Lau , Jane Spetzler , Janos Tibor Kodra , Lars Linderoth , Patrick William Garibay , Per Sauerberg , Thomas Kruse
发明人: Alice Ravn Madsen , Birgit Wieczorek , Jacob Kofoed , Jesper Lau , Jane Spetzler , Janos Tibor Kodra , Lars Linderoth , Patrick William Garibay , Per Sauerberg , Thomas Kruse
IPC分类号: C07K14/605
CPC分类号: C07K14/605 , A61K47/542
摘要: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH2)x—CO—* Chem. 2: HOOC—C6H4-0-(CH2)y—CO—* Chem. 3: R2—C6H4—(CH2)z—CO—*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *—NH—(CH2)2-(0-(CH2)2)k-0-(CH2)n—CO—*. wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
摘要翻译: 本发明涉及GLP-1类似物的衍生物,其类似物包含在对应于GLP-1(7-37)(SEQ ID NO:1)的第18位的位置处的第一个K残基,另一个的第二个K残基 位置和与GLP-1(7-37)相比最多12个氨基酸变化; 该衍生物分别包含通过接头分别连接到所述第一和第二K残基的两个伸长部分,其中伸长部分选自Chem。 1,Chem。 2和Chem。 3:化学式:HOOC-(CH2)x-CO- * 2:HOOC-C6H4-0-(CH2)y-CO- * Chem。 3:R2-C6H4-(CH2)z-CO- *,其中x是6-18的整数,y是3-17的整数,z是1的整数 -5和R2是摩尔质量不高于150Da的基团; 连接体包括Chem。 4:* -NH-(CH 2)2 - (O-(CH 2)2)k -O-(CH 2)n -CO- *。 其中k是1-5的整数,n是1-5的整数; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病,以及相应的新型肽和侧链中间体。 该衍生物适用于口服给药。
-
公开(公告)号:US20100292133A1
公开(公告)日:2010-11-18
申请号:US12676453
申请日:2008-09-05
申请人: Jane Spetzler , Lauge Schäffer , Jesper Lau , János Tibor Kodra , Kjeld Madsen , Patrick William Garibay , Jacob Kofoed , Steffen Reedtz-Runge , Henning Thøgersen , Igrid Pettersson
发明人: Jane Spetzler , Lauge Schäffer , Jesper Lau , János Tibor Kodra , Kjeld Madsen , Patrick William Garibay , Jacob Kofoed , Steffen Reedtz-Runge , Henning Thøgersen , Igrid Pettersson
CPC分类号: C07K14/605 , A61K38/00
摘要: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.
摘要翻译: 本发明涉及截短的GLP-1类似物,特别是GLP-1类似物,其是修饰的GLP-1(7-35)(SEQ ID No.1),其具有:i)总共2,3,4,5,6 ,7,8或9个氨基酸取代,其包括a)在等同于GLP-1(7-35)的位置22的位置上的Glu残基,和b)Arg 在等同于GLP-1(7-35)的第26位的位置上的残基; 以及其衍生物,以及治疗用途和组合物。 这些类似物和衍生物是高度有效的,对GLP-1受体以及GLP-1受体的细胞外结构域具有良好的结合亲和力,这与具有潜在的长效,稳定的GLP-1化合物具有潜在的相关性 每周一次行政。
-
公开(公告)号:US20130338068A1
公开(公告)日:2013-12-19
申请号:US13883946
申请日:2011-11-09
IPC分类号: C07K14/605
CPC分类号: C07K14/605 , A61K47/542
摘要: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from HOOC—(CH2)x—CO-*, and Chem. 1: HOOC—C6H4-0-(CH2)y—CO-*, Chem. 2: in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises *-NH—(CH2)q—CH[(CH2)w—NH2]—CO-*, Chem. 3: wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration.
摘要翻译: 本发明涉及GLP-1类似物的衍生物,其类似物包含在对应于GLP-1(7-37)(SEQ ID NO:1)的第18位的位置处的第一个K残基,另一个的第二个K残基 位置和与GLP-1(7-37)相比最多12个氨基酸变化; 该衍生物分别包含通过接头分别连接到所述第一和第二K残基的两个伸长部分,其中伸长部分选自HOOC-(CH 2)x -CO- *和Chem。 1:HOOC-C6H4-0-(CH2)y-CO- *,Chem。 2:其中x是6-18的整数,y是3-17的整数; 并且连接体包含* -NH-(CH 2)q-CH [(CH 2)w -NH 2] -CO - *, 3:其中q是0-5的整数,w是0-5的整数; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病,以及相应的新型肽和侧链中间体。 衍生物有效,延长,适合口服。
-
公开(公告)号:US09006178B2
公开(公告)日:2015-04-14
申请号:US13883946
申请日:2011-11-09
IPC分类号: A61K38/26 , A61P3/10 , A61P7/12 , C07K14/605 , A61K38/28 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K47/48
CPC分类号: C07K14/605 , A61K47/542
摘要: The invention relates to a derivative of a GLP-1 analog, which analog comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4-0-(CH2)y—CO—*, in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NH2]—CO—*, wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration.
摘要翻译: 本发明涉及GLP-1类似物的衍生物,其类似物包含在对应于GLP-1(7-37)(SEQ ID NO:1)的第18位的位置处的第一个K残基,另一个的第二个K残基 位置和与GLP-1(7-37)相比最多12个氨基酸变化; 该衍生物分别包含通过接头分别连接到所述第一和第二K残基的两个伸长部分,其中伸长部分选自Chem。 1:HOOC-(CH 2)x-CO- *,和Chem。 2:HOOC-C6H4-0-(CH2)y-CO- *,其中x是6-18的整数,y是3-17的整数; 连接体包括Chem。 3:* -NH-(CH 2)q-CH [(CH 2)w -NH 2] -CO- *,其中q是0-5的整数,w是0-5的整数 ; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病,以及相应的新型肽和侧链中间体。 衍生物有效,延长,适合口服。
-
公开(公告)号:US20140303083A1
公开(公告)日:2014-10-09
申请号:US14343152
申请日:2012-09-06
申请人: Jesper Lau , Paw Bloch , Jacob Kofoed , Patrick William Garibay
发明人: Jesper Lau , Paw Bloch , Jacob Kofoed , Patrick William Garibay
IPC分类号: C07K14/605
CPC分类号: C07K14/605 , A61K38/00 , A61K38/26
摘要: The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC—(CH2)x-CO—*, and Chem. 16: HOOC—C6H4-O—(CH2)y-CO—*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *—NH—CH(CH2OH)—CO—*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases.
摘要翻译: 本发明涉及GLP-1肽的衍生物,该肽与GLP-1(7-37)(SEQ)相比具有两个Lys残基,即第一和第二Lys残基,最多八个氨基酸变化 SEQ ID NO:3),该衍生物分别包含通过接头分别连接到所述第一和第二Lys残基的ε氨基的两个伸长部分,其中伸长部分选自Chem。 15:HOOC-(CH 2)x-CO- *,和Chem。 16:HOOC-C6H4-O-(CH2)y-CO- *,其中x是10-16的整数,y是8-12的整数; 并且连接体包含第一连接体元件* -NH-CH(CH 2 OH)-CO- *。 优选的接头是g Glu-Ser-Ser-Gly-Ser-Ser-Gly(SEQ ID NO:2)。 本发明的衍生物具有非常好的效力,并且与GLP-1受体具有非常好的结合。 本发明还涉及衍生物的药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病。
-
公开(公告)号:US20110275559A1
公开(公告)日:2011-11-10
申请号:US12993015
申请日:2009-05-18
IPC分类号: A61K38/22 , A61P3/04 , C07K14/575
CPC分类号: C07K14/575 , A61K47/542
摘要: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.
摘要翻译: 本发明涉及用包含四唑或羧酸基团的一种或多种血清白蛋白结合侧链衍生的PYY或PP肽衍生物或其类似物。 此外,本发明涉及本发明的组合物和治疗对Y受体调节作用的病症的方法。
-
公开(公告)号:US20130035285A1
公开(公告)日:2013-02-07
申请号:US13637454
申请日:2011-03-28
申请人: Jesper F. Lau , Thomas Kruse , Lars Linderoth , Henning Thoegersen , Jacob Kofoed , Kirsten Dahl
发明人: Jesper F. Lau , Thomas Kruse , Lars Linderoth , Henning Thoegersen , Jacob Kofoed , Kirsten Dahl
CPC分类号: C07K14/605 , A61K38/00 , A61K38/26 , A61K38/28 , A61K47/542 , A61K47/545
摘要: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
摘要翻译: 本发明涉及新颖的肽化合物,其具有延长的作用曲线和改善的溶解性和稳定性,在治疗中使用该化合物,包括向有需要的患者施用化合物,以及使用 药物制造中的化合物。 本发明的化合物在治疗高血糖症,糖尿病和肥胖以及与高血糖症,糖尿病和肥胖相关的各种疾病或病症方面特别有意义。
-
-
-
-
-
-
-
-
-